902 ORAL Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

首页> 外文期刊>European Journal of Cancer Supplements >902 ORAL Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

【24h】

902 ORAL Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

机译：902口服紫杉醇-卡铂-吉西他滨（TCG）与紫杉醇-卡铂（TC）作为卵巢癌女性的一线治疗：GCIG III组随机研究（AGO-OVAR 9，GINECO-TCG，NSGO-OC-0102）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) co [J] . Bois A, Sehouli J, Lund B, International journal of gynecological cancer: official journal of the International Gynecological Cancer Society . 2005,第Suppla3期

机译：紫杉醇-卡铂-吉西他滨（TCG）作为卵巢癌的一线治疗：前瞻性多中心II期研究（AGO-OVAR 8），然后进行前瞻性随机III期GCIG组间研究（AGO-OVAR 9，GINECO-TCG，NSGO） -OC-0102）公司
2. 915 POSTER Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer. mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO [J] . European Journal of Cancer Supplements . 2005,第2期

机译：915海报在晚期卵巢癌的一线治疗中，紫杉醇/卡铂（TC）与紫杉醇/卡铂，然后是拓扑替康（TOP）。 AGO OVAR和GINECO的妇科癌症间研究小组（GCIG）III期临床试验的结果
3. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial. [J] . Pujade Lauraine E, Bois A, Goupil A, International journal of gynecological cancer: official journal of the International Gynecological Cancer Society . 2005,第Suppla3期

机译：表柔比星/紫杉醇/卡铂（TEC）与紫杉醇/卡铂（TC）在卵巢癌FIGO IIB-IV期一线治疗中的比较。 AGO-GINECO GCIG组间III期随机试验的结果。
4. EORTC-1203-GITCG - the INNOVATION-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus pertuzumab in the perioperative treatment of HER2 positive gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group Korean Cancer Study Group and Dutch Upper GI-Cancer group [O] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, 2019

机译：EORTC-1203-GITCG-创新试验：单纯化疗与化疗加曲妥珠单抗相比与化疗加曲妥珠单抗加帕妥珠单抗在围手术期治疗HER2阳性胃和胃食管交界处腺癌对病理反应率的影响：随机阶段EORTC-胃肠道癌组韩国癌症研究组和荷兰上消化道癌组的II组间试验
5. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group [O] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, 2019

机译：EORTC-1203-GITCG - “创新”-Trial：单独的化疗与化疗加上曲妥珠单抗，与化疗加曲妥珠单抗Plus Pertuzumab在病理反应率上的围手术期治疗中：随机阶段II-族胃肠道癌组，韩国癌症研究组和荷兰上GI-癌组的IN-CONTGROUP试验

902 ORAL Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

著录项

相似文献

相关主题

期刊订阅